Pulmonary hypertension (PH) is a disease with a complex etiology and high mortality rate. Abnormal pulmonary vasoconstriction and pulmonary vascular remodeling lead to an increase in mean pulmonary arterial blood pressure for which, and there is currently no cure. Junctophilin-2 (JP2) is beneficial for the assembly of junctional membrane complexes, the structural basis for excitationcontraction coupling that tethers the plasma membrane to the sarcoplasmic reticulum/endoplasmic reticulum and is involved in maintaining intracellular calcium concentration homeostasis and normal muscle contraction function. Recent studies have shown that JP2 maintains normal contraction and relaxation of vascular smooth muscle. In some experimental studies of drug treatments for PH, JP2 expression was increased, which improved pulmonary vascular remodeling and right ventricular function. Based on JP2 research to date, this paper summarizes the current understanding of JP2 protein structure, function, and related heart diseases and mechanisms and analyzes the feasibility and possible therapeutic strategies for targeting JP2 in PH.
基金:
National Natural Science Foundation of China [81700055]; Outstanding Talent Research Funding of Xuzhou Medical University [D2016021]; Youth Natural Foundation of the Science and Technology Department of Jiangsu Province [BK20160229]
第一作者单位:[1]Xuzhou Med Univ, Dept Physiol, Xuzhou 221004, Jiangsu, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Tan Rubin,Li Cui,Xu Chuan,et al.Targeting JP2: A New Treatment for Pulmonary Hypertension[J].OXIDATIVE MEDICINE AND CELLULAR LONGEVITY.2021,2021:doi:10.1155/2021/2003446.
APA:
Tan, Rubin,Li, Cui,Xu, Chuan,Wu, Qi,Gao, Liping...&Cui, Jie.(2021).Targeting JP2: A New Treatment for Pulmonary Hypertension.OXIDATIVE MEDICINE AND CELLULAR LONGEVITY,2021,
MLA:
Tan, Rubin,et al."Targeting JP2: A New Treatment for Pulmonary Hypertension".OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2021.(2021)